576 related articles for article (PubMed ID: 35185932)
21. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
22. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
23. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
24. Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.
Pan S; Wang F; Jiang J; Lin Z; Chen Z; Cao T; Yang L
Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):153-162. PubMed ID: 36437159
[TBL] [Abstract][Full Text] [Related]
25. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
26. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
27. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
28. Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells.
Maddineni S; Silberstein JL; Sunwoo JB
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580928
[TBL] [Abstract][Full Text] [Related]
29. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
Schmidt P; Raftery MJ; Pecher G
Front Immunol; 2020; 11():611163. PubMed ID: 33488617
[TBL] [Abstract][Full Text] [Related]
30. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.
Daher M; Rezvani K
Curr Opin Immunol; 2018 Apr; 51():146-153. PubMed ID: 29605760
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
32. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
[TBL] [Abstract][Full Text] [Related]
33. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
Zhu H; Kaufman DS
Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
[TBL] [Abstract][Full Text] [Related]
34. Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles.
Goldenson BH; Zhu H; Wang YM; Heragu N; Bernareggi D; Ruiz-Cisneros A; Bahena A; Ask EH; Hoel HJ; Malmberg KJ; Kaufman DS
Front Immunol; 2020; 11():561553. PubMed ID: 33178188
[TBL] [Abstract][Full Text] [Related]
35. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
Ruppel KE; Fricke S; Köhl U; Schmiedel D
Front Immunol; 2022; 13():822298. PubMed ID: 35371071
[TBL] [Abstract][Full Text] [Related]
36. Next Generation Natural Killer Cells for Cancer Immunotherapy.
Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
Front Immunol; 2022; 13():886429. PubMed ID: 35720306
[TBL] [Abstract][Full Text] [Related]
37. Natural killer cells: a promising immunotherapy for cancer.
Chu J; Gao F; Yan M; Zhao S; Yan Z; Shi B; Liu Y
J Transl Med; 2022 May; 20(1):240. PubMed ID: 35606854
[TBL] [Abstract][Full Text] [Related]
38. A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors.
Goulding J; Yeh WI; Hancock B; Blum R; Xu T; Yang BH; Chang CW; Groff B; Avramis E; Pribadi M; Pan Y; Chu HY; Sikaroodi S; Fong L; Brookhouser N; Dailey T; Meza M; Denholtz M; Diaz E; Martin J; Szabo P; Cooley S; Ferrari de Andrade L; Lee TT; Bjordahl R; Wucherpfennig KW; Valamehr B
Med; 2023 Jul; 4(7):457-477.e8. PubMed ID: 37172578
[TBL] [Abstract][Full Text] [Related]
39. Clinical development of natural killer cells expressing chimeric antigen receptors.
Golden RJ; Fesnak AD
Transfus Apher Sci; 2021 Feb; 60(1):103065. PubMed ID: 33468407
[TBL] [Abstract][Full Text] [Related]
40. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
